Hunter Associates Investment Management LLC Has $6.62 Million Position in Eli Lilly and Company (NYSE:LLY)

Hunter Associates Investment Management LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 9.1% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 8,014 shares of the company’s stock after selling 802 shares during the period. Eli Lilly and Company accounts for about 1.0% of Hunter Associates Investment Management LLC’s portfolio, making the stock its 26th largest position. Hunter Associates Investment Management LLC’s holdings in Eli Lilly and Company were worth $6,619,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Garner Asset Management Corp raised its holdings in Eli Lilly and Company by 2.3% during the fourth quarter. Garner Asset Management Corp now owns 532 shares of the company’s stock worth $411,000 after buying an additional 12 shares during the last quarter. Brighton Jones LLC raised its holdings in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the last quarter. Orion Capital Management LLC raised its holdings in Eli Lilly and Company by 2.5% during the fourth quarter. Orion Capital Management LLC now owns 1,610 shares of the company’s stock worth $1,243,000 after buying an additional 40 shares during the last quarter. Finally, Bank Pictet & Cie Europe AG raised its holdings in Eli Lilly and Company by 4.1% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company’s stock worth $49,993,000 after buying an additional 2,568 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Hsbc Global Res downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. Erste Group Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target on the stock. UBS Group reduced their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,012.22.

Eli Lilly and Company Stock Up 0.4%

Eli Lilly and Company stock opened at $790.23 on Friday. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The firm has a 50 day moving average price of $767.03 and a 200-day moving average price of $800.01. The company has a market capitalization of $748.93 billion, a P/E ratio of 64.30, a P/E/G ratio of 1.15 and a beta of 0.40. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the prior year, the company earned $2.58 earnings per share. The firm’s revenue was up 45.2% on a year-over-year basis. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.76%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.